Ricrolin®+ in combination with a medical device emitting UV-A for ophthalmic use, is indicated in the conservative treatment of keratoconus and ectatic pathologies. The treatment is particularly indicated for:
all forms of corneal ectasia, genetic or iatrogenic.
progressive keratoconus (clinically or instrumentally documented) and for anomalies of the cornea.
CXL by iontophoresis procedure:
EPI-ON procedure: there is no de-epithelialization phase
Permeation phase: penetration of riboflavin into the stroma through the application of a low-intensity electric field generated by the I-ON CXL device. By fixing the current to 1mA, the iontophoresis phase lasts only 5 minutes.
UV-A irradiation phase provided using the VEGA LAMP 10mW for 9 minutes
Ricrolin® + is a Class IIb Medical Device, CE0373 Marking (ISS) - Made by SOOFT and distributed by Horus Pharma. - The IONTOFOR CXL® corneal electrode is a class IIa medical device, CE0051 (IMQ), manufactured by SOOFT and distributed by Horus Pharma. The PROTENS ELITE 4848LE return electrode is a class I medical device manufactured by BIOPROTECH for SOOFT and distributed by Horus Pharma. - The ION-CXL® current generator is a class IIB medical device (BIOS) manufactured by IACER and distributed by Horus Pharma. - "This medical device is a regulated health product which, under this regulation, bears the CE mark" - Read the instruction leaflet carefully before use.